Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC 

Gao-Jun Teng, MD, of Zhongda Hospital, Medical School, Southeast University, discusses findings from the phase 2 CARES-005 trial (NCT04559607) of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable hepatocellular carcinoma.

Videos

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Gao-Jun Teng, MD

Articles

Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC